secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001193125-24-152309
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit raises $200M, expands ivonescimab license to LAMEA regions
-----------------------------------------------------------------

- Raised $200M via private placement of 22.2M shares at $9.00/share, a premium to the prior close.
- Expanded ivonescimab license territory to Latin America, Middle East, Africa; $15M upfront plus up to $55M milestones.
- Net proceeds will fund ivonescimab clinical development and general corporate purposes.
- Registration rights agreement filed; resale registration statement expected within 60 days of closing.
- Amendment strengthens data-sharing provisions for global ivonescimab trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000119312524152309/0001193125-24-152309-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000119312524152309/d768276d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-152309

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer